|Bid||19.60 x 1800|
|Ask||20.73 x 900|
|Day's Range||19.58 - 19.86|
|52 Week Range||0.09 - 21.95|
|Beta (3Y Monthly)||0.61|
|PE Ratio (TTM)||24.37|
|Forward Dividend & Yield||0.79 (3.94%)|
|1y Target Est||N/A|
The president of Japan's Olympic Committee, Tsunekazu Takeda, has been indicted in France on allegations of corruption, an official has confirmed, related to his country's successful bid to host the 2020 Olympics. Lauren Anthony reports.
France’s Safran is attractive because of its jet-engine venture with the U.S. firm. Also looking good: Hexcel, Linde, Alphabet, Takeda Pharmaceutical, and a soon-to-be-broken-up DowDuPont.
Takeda Pharmaceutical wrapped its $62 billion acquisition of Shire last week. CEO Christophe Weber predicts it won't be the last merger in the hot biopharma sector.
Big pharmaceutical companies have begun 2019 with a bang. $62 billion buyout of Shire Plc have signaled the acquisition appetite in the space is strong. To understand the pipeline still ahead and the rationale for such massive mergers and acquisitions, TheStreet joined Takeda Pharmaceutical's CEO Christophe Weber on the New York Stock Exchange, shortly after his company rang the opening bell to celebrate the Japanese giant's U.S. listing.
The president of Japan's Olympic Committee, Tsunekazu Takeda, is under formal investigation in France for suspected corruption related to Japan's successful bid for the 2020 Olympic Games, a French judicial source said on Friday. French financial prosecutors investigating a multi-million dollar payment made by Japan's bidding committee to a Singaporean consultancy questioned Takeda in Paris and he was placed under formal investigation on Dec. 10, the source told Reuters.
The president of Japan’s Olympic Committee, Tsunekazu Takeda, has been placed under formal investigation on corruption allegations in France related to Japan’s winning bid to host the 2020 Olympic Games. Mr Takeda, who is helping to put together Japan’s Olympic games next year, was placed under investigation last month on suspicion of “active corruption”, said a spokesperson for the Paris prosecutor’s office.
The International Olympic Committee's ethics commission on Friday opened a file on Japan Olympic Committee chief Tsunekazu Takeda after a judicial source in France said he had been indicted by French prosecutors over the successful bid for the 2020 Olympic Games. The IOC Ethics commission has opened a file and will continue to monitor the situation - and is meeting today.
Takeda's global acquisition of Shire creates an expanded Takeda Canada to bring better health and a brighter future to Canadians
Mersana executives discussed data from its ovarian and lung cancer drug trial Wednesday. The biotech also plans to disclose its next clinical candidate in the second half of 2019.
Takeda will consider selling businesses from its Nycomed acquisition in 2011, as Japan’s largest pharmaceutical group seeks to divest $10bn of assets after completing a £46bn deal to buy Shire. Christophe ...
For one, debt is a huge issue, with net borrowings more than doubling as Takeda takes on about $30 billion in debt to acquire Shire. S&P Global Ratings downgraded Takeda on Tuesday, questioning how quickly it will be able to repair worsening financial ratios. In addition, Weber needs to whip the new Takeda into shape as competition heats up in the pharmaceutical industry.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 7) Axsome Therapeutics Inc (NASDAQ: AXSM ) ( reported positive ...
Takeda Pharmaceutical has completed its £46bn acquisition of Shire, catapulting the 237-year-old Japanese group into one of the world’s largest drugmakers with combined revenues of $31bn . The completion ...
Takeda’s purchase was the world’s biggest announced acquisition of 2018, transforming the 237-year-old Japanese company into a top 10 drugmaker with lucrative therapies for rare diseases and a sizable footprint in the U.S. Already in 2019, the Takeda deal has been trumped in size by Bristol-Myers Squibb Co.’s $74 billion agreement last week to buy Celgene Corp. Takeda and Shire’s combined revenue catapult it into the ranks of the global pharmaceutical majors -- the first Japanese company to reach the top 10.
The joint company is expected to bring in more than $31 billion in annual revenue from a portfolio of cancer, neurological, gastrointestinal and rare disease drugs.
Takeda Pharmaceutical Company Limited (4502.T) (TAK) (“Takeda”) today announced the completion of its acquisition of Shire plc (“Shire”), becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Takeda now has an attractive, expanded geographic footprint and leading position in Japan and the U.S., bringing its highly-innovative medicines to approximately 80 countries/regions with dedicated employees worldwide. Takeda’s R&D efforts are focused on its four therapeutic areas of Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases, with targeted R&D investment also committed to Plasma-Derived Therapies (PDT) and Vaccines.
Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.
Takeda Pharmaceutical is unlikely to sell its over-the-counter (OTC) drug business even amid pressure to improve its finances as it closes a $59 billion takeover of London-listed Shire, Chief Executive Christophe Weber said on Monday. After the Shire deal, which closes on Tuesday, Takeda will have a stronger pipeline and be counted among the top 10 drugmakers by sales globally. "It's not our first priority," Weber told a news conference when asked whether Takeda would sell its OTC business.
Biopharmaceutical company Mersana Therapeutics Inc. said Friday that it will discontinue development of its XMT-1522 cancer treatment, following a strategic evaluation by the company. The stock is currently halted for news. Instead, the company will focus its resources on advancing XMT-1536. XMT-1522 was being developed with its partner, Takeda Pharmaceutical Co. Ltd. . "We have made the difficult decision to terminate the further development of XMT-1522 despite a favorable emerging profile of efficacy and tolerability due to the competitive environment for HER2-targeted therapies," said Mersana Chief Executive Anna Protopapas. The company said it plans to report phase 1 trial dose escalation data in the first half of 2019. The stock has plunged 56% over the past three months, while the iShares Nasdaq Biotechnology ETF has lost 17% and the S&P 500 has shed 16%.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) notes Shire plc’s (“Shire”) announcement that the Royal Court of Jersey (the “Jersey Court”) has today sanctioned the scheme of arrangement (the “Scheme”) pursuant to which the proposed acquisition of Shire by Takeda (the “Acquisition”) is being implemented. As previously announced, it is expected that the Scheme will become effective, and that closing of the Acquisition will take place, on January 8, 2019, when a copy of the Jersey Court order is delivered to the registrar of companies in Jersey. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, research and development- driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.